Biomedical Advanced Research and Development Authority (BARDA)
BARDA is a U.S. federal agency within HHS/ASPR that funds, develops, and procures medical countermeasures — vaccines, therapeutics, diagnostics, and devices — against CBRN threats, pandemic influenza, and emerging infectious diseases for national stockpiles and emergency deployment.
- Company typePublic
- Founded2006
- HeadquartersWashington, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Biomedical Advanced Research and Development Authority (BARDA) does
BARDA (Biomedical Advanced Research and Development Authority) is a U.S. federal government agency within the Department of Health and Human Services, operating under the Administration for Strategic Preparedness and Response (ASPR). Established by the Project BioShield Act of 2004, BARDA's mandate is to fund and coordinate the advanced research, development, regulatory approval, procurement, and stockpiling of medical countermeasures (MCMs) — vaccines, therapeutics, diagnostics, and medical devices — against chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. The agency operates through four primary divisions (CBRN, Influenza & Emerging Infectious Diseases, Detection/Diagnostics/Devices Infrastructure, and Regulatory & Quality Affairs) plus special initiatives including Project BioShield, Project NextGen (a $5B COVID-19 successor program with NIAID), the BioMaP-Consortium for domestic biomanufacturing, DRIVe for transformative technology acceleration, and FASTx for flexible therapeutics platforms.
BARDA funds external partners — large pharmaceutical manufacturers (Moderna, GSK, Sanofi, CSL Seqirus), specialty biotechs (Mapp Biopharmaceutical, Cidara, Paratek, Basilea), diagnostics developers (Pattern Bioscience, Prenosis, Spectral AI, RIVANNA, GE HealthCare), and biomanufacturing firms (Ginkgo Bioworks, Just–Evotec, SCHOTT Pharma) — through contract mechanisms including the Broad Agency Announcement (BAA), Easy BAA, TechWatch meetings, and Other Transaction Authorities. Its business model is federal procurement rather than commercial sales: BARDA does not sell products but funds development and acquires countermeasures for the Strategic National Stockpile (SNS), Vendor Managed Inventory (VMI), and Other Designated Storage Spaces (ODSS) for emergency deployment to state and local health departments, healthcare providers, and first responders.
The agency has facilitated 115 FDA Approvals, Licensures, and Clearances for supported products since inception. It coordinates regulatory pathways through a formal BARDA-FDA Memorandum of Understanding, operates a Clinical Studies Network (CSN) supporting 60+ FDA applications and 19 quality audits in 2025, and integrates with HHS, DHS, and DOD through the Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) governance structure. Customers are fundamentally U.S. federal, state, and local government entities and the healthcare/first-responder workforce that administers MCMs during declared public health emergencies.
Biomedical Advanced Research and Development Authority (BARDA) firmographics
Firmographics- Name
- Biomedical Advanced Research and Development Authority (BARDA)
- Legal name
- Biomedical Advanced Research and Development Authority (BARDA)
- Website
- http://www.medicalcountermeasures.gov
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- BARDA is a U.S. federal agency within HHS/ASPR that funds, develops, and procures medical countermeasures — vaccines, therapeutics, diagnostics, and devices — against CBRN threats, pandemic influenza, and emerging infectious diseases for national stockpiles and emergency deployment.
- Ownership category
- akta.pro rank
Biomedical Advanced Research and Development Authority (BARDA) industry classification
Industry- Product category
- Government Health and Medical Countermeasures
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Federal & Federally-Sponsored Credit Agencies (6111)
- akta.pro primary industry
- Public Health Laboratories & Diagnostic Oversight (BPAIAJAF)
- akta.pro secondary industries
- National Development Banks & State Development Finance Institutions (DFIs) (BPADACAC), National Public Health Reference Laboratories (HLAJAIAA)
Keywords
Where Biomedical Advanced Research and Development Authority (BARDA) is headquartered
LocationHeadquarters
- HQ city
- Washington
- HQ country
- United States
- HQ region
- North America
Markets served
Biomedical Advanced Research and Development Authority (BARDA) business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Others
Distribution channels4 records
Marketing channels6 records
Biomedical Advanced Research and Development Authority (BARDA) product offering
Product offeringCore offering
BARDA is a U.S. federal government agency that funds and accelerates the development, manufacture, and procurement of medical countermeasures (MCMs) — including vaccines, therapeutics, diagnostics, and devices — to protect the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats. It partners with industry, academia, and other government agencies through contracts, grants, and other transaction authorities to advance MCMs from early research through advanced development and FDA approval.
Product overview
BARDA is a U.S. government agency within HHS that develops and funds medical countermeasures (MCMs) against public health threats. The organization operates through multiple interconnected programs: CBRN programs address chemical, biological, radiological, and nuclear threats; IEID focuses on influenza and emerging infectious diseases; DDDI develops diagnostics and devices; and special initiatives like Project BioShield, Project NextGen, and the BioMaP-Consortium accelerate MCM development and domestic manufacturing. BARDA funds external partners through mechanisms including the Broad Agency Announcement (BAA), Easy BAA, and TechWatch program. The Clinical Studies Network and Regulatory & Quality Affairs division provide operational support for product development through FDA approval.
Differentiator
Problem solved
Functional benefit
Brands
- Project BioShield: A program to accelerate research, development, procurement, and availability of effective medical countermeasures against CBRN threats.
- Project NextGen
- FASTx (Flexible and Strategic Therapeutics)
- PRISM
- DRIVe (Division of Research, Innovation & Ventures)
- BioMaP-Consortium
Products and services
- Medical Countermeasure Development Funding Funding and partnership programs that support the advanced research, development, and manufacturing of vaccines, therapeutics, diagnostics, and medical devices to address public health emergencies and CBRN threats. Customers are biopharmaceutical companies, research institutions, and product developers.
- Medical Countermeasure Procurement Procurement and stockpiling of approved medical countermeasures for inclusion in the Strategic National Stockpile and other federal reserves, providing guaranteed offtake to manufacturers.
- Other Transaction Authority (OTA) Agreements Flexible contracting mechanism used to enter into prototype, research, and production agreements with industry and academic partners outside of traditional FAR-based procurement, enabling faster partnership formation.
Quantifiable outcome
- 115 FDA approvals, licensures, and clearances for BARDA-supported products
- +1 more outcomes
Companies that use Biomedical Advanced Research and Development Authority (BARDA)
Customer profileSegments3 records
Ideal customer profiles2 records
Biomedical Advanced Research and Development Authority (BARDA) technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature5 records
Biomedical Advanced Research and Development Authority (BARDA) partnerships and signals
Strategic signalPartnerships
36 partnerships are on record, tiered core and minor.
- Mapp BiopharmaceuticalcoreBARDA is seeking vaccine candidates based on the platform used in Merck's Ervebo, while supporting the transfer of MBP134, an experimental monoclonal antibody therapy developed with Mapp Biopharmaceutical, for compassionate use and clinical trials during the Ebola Bundibugyo outbreak response.
- University of OxfordminorGlobal coordination partner in Ebola Bundibugyo outbreak response alongside BARDA, UNICEF, and CEPI for vaccine development efforts.
- Coalition for Epidemic Preparedness Innovations (CEPI)coreGlobal health partner committing over $61 million in initial funding across Ebola Bundibugyo vaccine candidates during the 2026 outbreak response.
- SCHOTT PharmacoreOver $60 million investment largely funded by BARDA to strengthen U.S. pharmaceutical supply chain through expanded vial production in Lebanon, Pennsylvania. Significantly increases annual production capacity for core vials while tripling local capacity for RTU vials and specialty containers for biologics, vaccines, and targeted cancer treatments.
- RIVANNAcoreNearly $9.92 million from BARDA to develop AI module for Accuro XV ultrasound platform. Expanded clinical studies from 2 to 8 sites nationwide following BARDA exercise of funding option. Study aims to develop first automated fracture detection algorithm from volumetric ultrasound imaging.
- Shionogi Inc.coreBARDA awarded Shionogi a Project BioShield contract for Fetroja (cefiderocol) as a countermeasure against drug-resistant bacterial infections and biothreat pathogens. Contract initially funded at $119 million with multiyear options up to $482 million total. Will establish U.S. drug product manufacturing, support procurement, and advance treatments for melioidosis and plague infections.
- Avita Medicalcore10-year agreement worth up to $25.5 million with BARDA to supply RECELL products for burn mass casualty incidents. Provides 3,000 units of FDA-approved wound care treatments along with logistics support, quality assurance, and deployment readiness services.
- Vericel Corporationcore$197 million contract from BARDA to support procurement, development, and clinical testing of cell therapy products. Funding aims to accelerate Vericel's pipeline of regenerative medicine solutions and scale up manufacturing.
- Just - Evotec BiologicscoreSelected by BARDA's Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) for a multi-year program to optimize biomanufacturing of monoclonal antibody therapeutics targeting Ebola and Sudan filovirus diseases. Agreement valued at up to $10 million if all options are activated.
- Spectral AIcore$31.7 million non-dilutive funding award from BARDA to accelerate development of DeepView System burn wound imaging platform. Supplements $54.9 million already committed under existing BARDA contract with total potential value up to $150 million. Supports additional features, FDA clearance efforts, and Phase II initiatives.
- Pattern BiosciencecoreBARDA contract valued at up to $40.9 million for Pattern Pneumonia ID/AST Panel pivotal trial. First culture-free, rapid phenotypic susceptibility testing panel for critically ill pneumonia patients, delivering results in hours rather than 2-4 days. Holds FDA Breakthrough Device Designation.
- GE HealthCarecore$35 million contract expansion with BARDA for AI-powered ultrasound solutions. Building on existing relationship for advanced medical imaging technologies.
- Basilea PharmaceuticacoreMulti-year collaboration with BARDA to advance clinical antifungal candidates including fosmanogepix and BAL2062 toward regulatory approval. Received USD 6 million payment, with potential for up to USD 147 million in additional non-dilutive funding upon milestone completion including phase 3 clinical studies.
- Paratek PharmaceuticalscoreBARDA Project BioShield contract valued at up to approximately $304 million for NUZYRA in pulmonary anthrax. Positive Animal Rule study results triggered additional oral NUZYRA procurement under the contract, supporting U.S. onshoring initiative.
- ASPRcoreASPR has launched $100 million Small Molecule Approaches for Rapid and Robust Treatment Prize coordinated by BARDA. Competition supports development of antiviral drug therapies targeting Togaviridae and Flaviviridae families including dengue, Zika, West Nile, and Chikungunya.
- Prenosiscore$20 million BARDA contract for developing integrated diagnostics and therapeutics for critical care conditions including sepsis. Supports commercial delivery of FDA-authorized Sepsis ImmunoScore and pivotal randomized controlled trial of AI-driven corticosteroid companion diagnostics in approximately 800 patients.
- Cidara TherapeuticscoreReceived $339.2 million BARDA award to support manufacturing and clinical development of CD388, an influenza preventative. CD388 received Breakthrough Therapy designation from the FDA. Company enrolled first patients in Phase 3 ANCHOR study.
- Ginkgo BioworkscoreAwarded contract up to $22.2 million through BARDA's BioMaP-Consortium to develop and strengthen domestic biomanufacturing of monoclonal antibodies targeting Ebola and Sudan viruses. Leading a multi-partner team including Advanced BioScience Laboratories, Isolere Bio by Donaldson, NeuImmune, and ProteoNic BV to scale production of Emory University's 1C3 and 1C11 mAbs cocktail.
- Advanced BioScience LaboratoriesminorPartner in Ginkgo-led multi-organization team for BARDA BioMaP-Consortium anti-filovirus mAb manufacturing project.
- Isolere Bio by DonaldsonminorPartner in Ginkgo-led multi-organization team for BARDA BioMaP-Consortium anti-filovirus mAb manufacturing project.
- NeuImmuneminorPartner in Ginkgo-led multi-organization team for BARDA BioMaP-Consortium anti-filovirus mAb manufacturing project.
- ProteoNic BVminorLicensed its 2G UNic vector technology to Ginkgo Bioworks for use in BARDA-funded anti-filovirus mAb manufacturing project through BioMaP-Consortium.
- Start2 GroupcoreBARDA partnership to launch $100 million antiviral prize competition aimed at developing broad-spectrum antivirals. Multi-year, tiered competition expected to start in early 2026 focusing on dengue and West Nile virus.
- True DiagnosticscoreApproximately $11 million BARDA project to develop rapid diagnostic test capable of detecting Ebola and Marburg viruses, focusing on accelerating biothreat response for future outbreak preparedness.
- Modernacore$590 million award from HHS through BARDA-funded Rapid Response Partnership Vehicle (RRPV) Consortium to accelerate mRNA-based pandemic influenza vaccine development. Supporting late-stage development, licensure of pre-pandemic vaccines, and expansion of clinical studies for up to five additional subtypes of pandemic influenza.
- Advanced Technology International (ATI)coreBARDA awarded agreement to ATI to serve as consortium management firm (CMF) for BioMaP-Consortium. ATI manages day-to-day operations including releasing, managing, and streamlining solicitations under the Consortium.
- FDAcoreBARDA-FDA Memorandum of Understanding for coordinated regulatory pathways, enhanced collaboration, and exchange of information and expertise on medical countermeasure development and approval.
- Department of Homeland SecuritycoreKey interagency partner in PHEMCE governance structure coordinating research, development, regulation, procurement, stockpiling, and deployment of medical countermeasures.
- Department of DefensecoreKey interagency partner in PHEMCE governance structure and coordinated medical countermeasure development. DoD has been briefed on BARDA programs including radiation/nuclear countermeasures.
- GSKcoreLong-standing BARDA partnership for pandemic influenza vaccine development and National Pre-Pandemic Influenza Vaccine Stockpile sustainment and modernization.
- SanoficoreLong-standing BARDA partnership for pandemic influenza vaccine development and National Pre-Pandemic Influenza Vaccine Stockpile sustainment and modernization.
- CSL SeqiruscoreLong-standing BARDA partnership for pandemic influenza vaccine development and National Pre-Pandemic Influenza Vaccine Stockpile sustainment and modernization.
- NIH/NIAIDcoreBARDA collaborates with NIAID on Project NextGen for next-generation COVID-19 vaccines and therapeutics. NIAID provides Phase I/IIa safety and immunogenicity trial infrastructure through its network sites.
- VaxxascoreHHS BARDA awarded $22 million to Vaxxas for needle-free vaccine administration technology using High-Density Microarray Patch (HD-MAP) platform to improve pandemic vaccine deployment.
- ModeX TherapeuticscoreExpanding partnership under Project NextGen to develop multispecific antibody (mAb) and RNA-expressed multispecific mAb for SARS-CoV-2.
- VaxartcoreProject NextGen partnership supporting Vaxart's oral vaccine candidate Phase 2b clinical trial for COVID-19.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Biomedical Advanced Research and Development Authority (BARDA) competitors and assessment
Company assessmentBroad incumbents
- National Institutes of Health (NIH) / NIAID: The U.S. federal health research agency that co-leads Project NextGen with BARDA and provides Phase I/IIa clinical trial infrastructure. Comparable as a federal R&D funding authority operating in infectious disease, vaccine, and therapeutic development.
- Centers for Disease Control and Prevention (CDC): U.S. federal public health agency coordinating disease response and stockpiling policy. Comparable to BARDA as a federal public health preparedness actor with overlapping interests in CBRN, influenza, and emerging infectious disease response.
- Defense Advanced Research Projects Agency (DARPA): U.S. federal R&D agency funding high-risk, high-impact technology development including biodefense and pandemic response. Comparable as a government program funding breakthrough biomedical research with non-dilutive contracts.
- Food and Drug Administration (FDA): U.S. federal regulator with which BARDA holds a formal MOU for coordinated medical countermeasure regulatory pathways. Comparable as a federal health agency deeply entangled with BARDA's development and approval processes.
- Administration for Strategic Preparedness and Response (ASPR): BARDA's direct parent organization within HHS, coordinating federal medical and public health emergency preparedness. Comparable as the immediate federal counterpart exercising oversight over BARDA's program portfolio.
Direct peers
- Coalition for Epidemic Preparedness Innovations (CEPI): International coalition funding vaccine development against epidemic threats. Comparable as a public-sector countermeasure funding entity that co-funds Ebola and pandemic influenza vaccine development alongside BARDA.
Others
- Biomedical Advanced Research and Development Authority (BARDA) DRIVe: BARDA's internal Division of Research, Innovation & Ventures focused on transformative health security technologies. Listed as an internal adjacent unit demonstrating the agency's own R&D venture-style funding arm.
- Biomedical Advanced Research and Development Authority — Project BioShield (sub-brand): BARDA's $5.6B special procurement program for CBRN medical countermeasures. Listed as an internal program equivalent that operates as a dedicated countermeasure acquisition vehicle.
Regional players
- European Health Emergency Preparedness and Response Authority (HERA): EU-level agency established to strengthen health emergency preparedness and countermeasure development. Comparable as a regional peer to BARDA with a similar mandate around CBRN and pandemic preparedness.
- UK Health Security Agency (UKHSA): UK government agency responsible for public health protection including pandemic preparedness. Comparable as a national-level public health security counterpart to BARDA in a different geography.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Biomedical Advanced Research and Development Authority (BARDA) social profiles
Digital presenceBiomedical Advanced Research and Development Authority (BARDA) financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biomedical Advanced Research and Development Authority (BARDA) leadership team
Management profileNumber of profiles
Biomedical Advanced Research and Development Authority (BARDA) funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biomedical Advanced Research and Development Authority (BARDA) M&A and investment
M&A and investmentM&A
Investments84 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biomedical Advanced Research and Development Authority (BARDA)
What does Biomedical Advanced Research and Development Authority (BARDA) do?
BARDA is a U.S. federal government agency that funds and accelerates the development, manufacture, and procurement of medical countermeasures (MCMs) — including vaccines, therapeutics, diagnostics, and devices — to protect the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats. It partners with industry, academia, and other government agencies through contracts, grants, and other transaction authorities to advance MCMs from early research through advanced development and FDA approval.
Is Biomedical Advanced Research and Development Authority (BARDA) a public or private company?
Biomedical Advanced Research and Development Authority (BARDA) is a public company. It is classified as state government owned and is currently operating.
When was Biomedical Advanced Research and Development Authority (BARDA) founded?
Biomedical Advanced Research and Development Authority (BARDA) was founded in 2006. It employs 501 to 1,000 people.
Where is Biomedical Advanced Research and Development Authority (BARDA) based?
Biomedical Advanced Research and Development Authority (BARDA) is headquartered in Washington, United States, in the North America region.
Who are Biomedical Advanced Research and Development Authority (BARDA)'s main competitors?
Broad incumbents on record are National Institutes of Health (NIH) / NIAID, Centers for Disease Control and Prevention (CDC), Defense Advanced Research Projects Agency (DARPA), Food and Drug Administration (FDA) and Administration for Strategic Preparedness and Response (ASPR). Coalition for Epidemic Preparedness Innovations (CEPI) is listed as a direct peer. Others are Biomedical Advanced Research and Development Authority (BARDA) DRIVe and Biomedical Advanced Research and Development Authority — Project BioShield (sub-brand). Regional players are European Health Emergency Preparedness and Response Authority (HERA) and UK Health Security Agency (UKHSA).
Does Biomedical Advanced Research and Development Authority (BARDA) have an API?
No public API is recorded for Biomedical Advanced Research and Development Authority (BARDA).
What industry is Biomedical Advanced Research and Development Authority (BARDA) in?
Biomedical Advanced Research and Development Authority (BARDA)'s product category is Government Health and Medical Countermeasures. Its primary akta.pro industry code is BPAIAJAF, Public Health Laboratories & Diagnostic Oversight, with a secondary code of BPADACAC, National Development Banks & State Development Finance Institutions (DFIs). Its NAICS code is 5417 and its SIC code is 8731.